Table of Contents Table of Contents
Previous Page  46 / 53 Next Page
Information
Show Menu
Previous Page 46 / 53 Next Page
Page Background

Pooled Efficacy in EXP2 (ALK

+

, Crizotinib Only)

and EXP3A (ALK

+

, Crizotinib + CT) cohorts

70

60

10

0

30

20

50

40

‒10

‒20

‒30

‒40

‒50

‒60

‒70

‒80

‒90

‒100

Best Change From Baseline (%)

EXP2+3

A (n=59)

ORR, n/N (%)

(95% CI)

41/59

(69)

(56, 81)

IC ORR, n/N

(%)

(95% CI)

25/37

(68)

(50, 82)

Median DOR,

mo (95% CI)

NR

(11.1,

NR)

DOR ≥6 mo,

n

/n (%)

20/41

(49)

Median PFS,

mo

(95% CI)

NR

(12.5,

NR)

• 37 patients (63%) had brain

metastases at baseline.

Off treatment or PD occurred

Complete response

Partial response

Stable disease

Progressive disease (PD)

Overall

a,b

70

60

10

0

30

20

50

40

‒10

‒20

‒30

‒40

‒50

‒60

‒70

‒80

‒90

‒100

Intracranial

a,b

CI, confidence interval; CT, chemotherapy; DOR, duration of response; mo, months; NR, not reached.

a

Patients with at least one on-study target lesion assessment as per independent central review were included. If any procedure was different and not interchangeable from the procedure at screening, the percent change from baseline could not be calculated and is

not displayed.

b

Complete response was defined as the disappearance of all target lesions; when nodal disease was included in target lesions, reversion to normal node size (<10 mm) prevented the percent change from baseline from reaching –100%. Some patients with a total

change from baseline of –100% are shown as partial responses due to the inclusion of non-target lesions in the summary.